1016546--3/13/2007--ALTAIR_NANOTECHNOLOGIES

related topics

{product, candidate, development}

{stock, price, share}

{acquisition, growth, future}

{cost, regulation, environmental}

{stock, price, operating}

{personnel, key, retain}

{loss, insurance, financial}

{property, intellectual, protect}

{regulation, government, change}

{interest, director, officer}

{debt, indebtedness, cash}

{competitive, industry, competition}

{customer, product, revenue}

We may continue to experience significant losses from operations Our quarterly operating results have fluctuated significantly in the past and will continue to fluctuate in the future, which could cause our stock price to decline. Our revenues have historically been generated from low-margin contract research services; if we cannot expand revenues from other products and services, our business will fail. Our patents and other protective measures may not adequately protect our proprietary intellectual property, and we may be infringing on the rights of others. Because our products are generally components of end products, the viability of many or our products is tied to the success of third parties' existing and potential end products. The commercialization of many of our technologies is dependent upon the efforts of commercial partners and other third parties over which we have no or little control. If we acquire or invest in other companies, assets or technologies and we are not able to integrate them with our business, or we do not realize the anticipated financial and strategic goals for any of these transactions, our financial performance may be impaired. We intend to expand our operations and increase our expenditures in an effort to grow our business. If we are unable to achieve or manage significant growth and expansion, or if our business does not grow as we expect, our operating results may suffer. Our competitors have more resources than we do, which may give them a competitive advantage. We will not generate substantial revenues from our life science products unless proposed products receive FDA approval and achieve substantial market penetration. As manufacturing becomes a larger part of our operations, we will become exposed to accompanying risks and liabilities. We have issued a $3,000,000 note to secure the purchase of the land and the building where our nanomaterials and titanium dioxide pigment assets are located. We may not be able to raise sufficient capital to meet future obligations. Our past and future operations may lead to substantial environmental liability. Certain of our experts and directors reside in Canada and may be able to avoid civil liability. We are dependent on key personnel. We may issue substantial amounts of additional shares without stockholder approval. The market price of our common shares is highly volatile and may increase or decrease dramatically at any time. We have never declared a cash dividend and do not intend to declare a cash dividend in the foreseeable future. We are subject to various regulatory regimes, and may be adversely affected by inquiries, investigations and allegations that we have not complied with governing rules and laws.

Full 10-K form ▸

1016546--3/13/2007--ALTAIR_NANOTECHNOLOGIES_INC